Patients and methodsWe designed a prospective study, which was approved by the local ethics committee. A total of 120 consecutive men with PC, who consented to undergo a genetic analysis of blood, were enrolled into the study. We obtained 5 ml of blood from each patient to containers with EDTA-K (Sarstedt, Nümbrecht, Germany). Clinical data acquired for analysis included age at diagnosis, PSA, and the Gleason score (GS). We used a pathological stage after radical prostatectomy (RP) and clinical staging (digital rectal examination, transrectal ultrasound, and bone scan) to classify patients into 2 groups: organ-confined PC when pT≤2c after RP or locally advanced/metastatic PC when cT3/4, pT≥3a after RP, pN1, or M1 in a bone scan.The median age of patients was 67 years (range, 48-87 years), and median PSA was 12.8 ng/ml (range, 3.44-2500 ng/ml). There were 72 patients (60.5%) with a GS of 6 or lower and 47 patients (39.5%) with a GS of 7 or higher; 39 patients were assigned to the organ-confined group, whereas 44 patients were considered as locally advanced / metastatic. The data on staging were unavailable in 37 patients. Our control group comprised umbilical cord blood samples obtained from 120 male newborns, whose parents agreed to an investigational use of samples.